Generally, new drugs approved by the U.S. Food and Drug Administration will not be reviewed until they have been available on the market at least 6-12 months (unique clinical exceptions may apply).
Once a formulary decisions is made, the Pharmacy and Therapeutics Committee will not re-evaluate the drug or drug class for another two years, unless there are significant changes in drug safety or efficacy that would prompt a second review.